Total and Unbound Bictegravir Concentrations and Viral Suppression in Cerebrospinal Fluid of Human Immunodeficiency Virus-Infected Patients (Spanish HIV/AIDS Research Network, PreEC/RIS 56)

Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors

(2016) Anthony T. Podany et al.   CLINICAL PHARMACOKINETICS

Central Nervous System Penetration of Antiretroviral Drugs: Pharmacokinetic, Pharmacodynamic and Pharmacogenomic Considerations

(2015) Eric H. Decloedt et al.   CLINICAL PHARMACOKINETICS

ING116070: A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in Cerebrospinal Fluid in HIV-1-Infected, Antiretroviral Therapy-Naive Subjects

(2014) S. L. Letendre et al.   CLINICAL INFECTIOUS DISEASES

Protein-Free Efavirenz Concentrations in Cerebrospinal Fluid and Blood Plasma Are Equivalent: Applying the Law of Mass Action To Predict Protein-Free Drug Concentration

(2013) L. B. Avery et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Etravirine in CSF is highly protein bound

(2013) A. Nguyen et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration

(2012) D. Croteau et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study

(2010) R. K. Heaton et al.   NEUROLOGY